High level of fluorescent oxidation products and worsening of asthma control over time

Respiratory Research

Table 1 Associations between Fluorescent oxidation products level at EGEA2 and evolution of asthma characteristics

Evolution of asthma characteristics	Fluorescent oxidation products (RFU/mL)
Evolution of asthma characteristics	n	OR (95% CI)	OR_adjusted (95% CI)
Persistent vs Improved (ref)
Current asthma^a	355 vs 38	1.30 (0.86–1.98)	1.19 (0.79–1.80)
Asthma attacks^a	115 vs 53	1.07 (0.74–1.53)	1.13 (0.74–1.72)
Poor asthma control^b	82 vs 31	0.93 (0.58–1.47)	0.84 (0.48–1.44)
Worsened vs Stable (ref)
Current asthma^a	18 vs 31	0.95 (0.54–1.66)	0.73 (0.39–1.39)
Asthma attacks^a	51 vs 202	1.10 (0.76–1.60)	1.08 (0.72–1.60)
Poor asthma control^b	46 vs 68	2.31 (1.33–4.00)	2.27 (1.32–3.90)

OR odds ratio expressed for an increase corresponding to the value of the interquartile range (distance between the 25th and 75th percentile) of FlOPs; adjusted for age, sex and smoking status. Results are presented as “Persistent versus Improved” (reference) and “Worsened versus Stable” (reference) between EGEA2 and EGEA3
^aamong 489 participants with ever asthma at both surveys; ^bamong 355 participants with current asthma at both surveys
Asthma attacks was defined by a positive answer to the following question: “Have you had an asthma attack in the last 12 months?”
Results in bold are statistically significant

ISSN: 1465-993X